Amylyx Pharmaceuticals, Inc.AMLXNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P55
Within normal range
vs 2Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 6.30% |
| Q3 2025 | -26.67% |
| Q2 2025 | 22.41% |
| Q1 2025 | -3.38% |
| Q4 2024 | 7.79% |
| Q3 2024 | -8.22% |
| Q2 2024 | -36.79% |
| Q1 2024 | -18.49% |
| Q4 2023 | 49.53% |
| Q3 2023 | 3.42% |
| Q2 2023 | 20.06% |
| Q1 2023 | 6.04% |
| Q4 2022 | -8.43% |
| Q3 2022 | 2.70% |
| Q2 2022 | 13.02% |
| Q1 2022 | 60.25% |
| Q4 2021 | 4.21% |
| Q3 2021 | 17.60% |
| Q2 2021 | 59.22% |
| Q1 2021 | 36.92% |
| Q4 2020 | 0.00% |